Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lisaftoclax + rituximab
- Development stage
- Unknown
- Lead developer
- Ascentage Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Lisaftoclax + rituximab is an investigational combination therapy comprised of lisaftoclax, an oral, highly selective BCL-2 inhibitor, and rituximab, a monoclonal antibody targeting CD20 on B-cells. **Lisaftoclax** inhibits the BCL-2 protein, promoting apoptosis in malignant cells overexpressing BCL-2 (notably chronic lymphocytic leukemia [CLL] and small lymphocytic lymphoma [SLL]), and is currently in late-stage development. **Rituximab** induces depletion of CD20-expressing B-cells through several mechanisms, including complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. This combination is being investigated, particularly in patients with treatment-naïve and relapsed/refractory CLL/SLL, for its synergistic effects and favorable safety profile[1][3][5][7][8].
- Brand names
- lisaftoclax
- Other names
- lisaftoclax + rituximab
02
Targets
BCL-2 (BCL-2 family)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on lisaftoclax + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lisaftoclax + rituximab.